Personalisation of Aspirin Adjuvant Therapy in Patients with Colorectal Cancer

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/GNT1138047

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Aspirin use is associated with a reduced risk of bowel cancer recurrence. However, benefit appears limited to a subset of patients, and some individuals experience side effects. We will analyse tumour samples from patients participating in the ASCOLT clinical trial of aspirin to identify molecular features that can predict who will benefit from aspirin. Predictive biomarkers would be of substantial clinical utility for guiding treatment, minimising toxicity and improving disease outcomes.

Funded Activity Details

Start Date: 01-01-2018

End Date: 01-01-2021

Funding Scheme: Project Grants

Funding Amount: $762,580.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Oncology and Carcinogenesis not elsewhere classified

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

adjuvant therapy | aspirin | biomarkers | colorectal cancer | patient outcomes

Related Links